A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Summary

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Obstructive Hypertrophic Cardiomyopathy

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Bristol-Myers Squibb

Last updated on ClinicalTrials.gov

August 19, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites